EGFR and non-small cell lung carcinoma: Furthermore, EGFR NeoAgs appear to act dominantly in the induction of T cell-mediated immunity in patients and were strongly associated with objective clinical responses, supporting the promising future of EGFR NeoAg-targeted peptide vaccines in treating EGFR-mutated NSCLC patients.